Company intelligence / Profile preview

Beijing Coway Pharmaceutical

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Coway Pharmaceutical has developed innovative oral drug delivery systems and commercialized at least one product—Wuwei Kushen Enteric-coated Capsule—for ulcerative colitis. The company integrates modern pharmaceutical science with traditional Chinese medicine approaches and has been recognized as a Nationally Innovative Technology Enterprise in China. Clinical results include approval of their lead IBD therapy and ongoing post-marketing studies to further assess safety and efficacy.

Therapeutic areas: Gastroenterology
Modalities: Small moleculeBiologicTraditional Chinese medicine-derived products
Industry: Biotech

Partnerships

Tsinghua University Industrial Research and Development Institute

Beyond the preview

Go deeper on Beijing Coway Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Coway Pharmaceutical.

Explore the full profile